Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $165 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a $165 price target.
February 15, 2024 | 2:17 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Alnylam Pharmaceuticals and maintained a $165 price target.
The reiteration of a Neutral rating and maintenance of a $165 price target by a reputable analyst suggests no significant short-term price movement is expected. The analysis indicates stability in the company's valuation according to Cantor Fitzgerald.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100